China's mRNA vaccine firm Abogen raises over US$700m from investors including Temasek

[BEIJING] China's Suzhou Abogen Biosciences said on Thursday it has raised over US$700 million to support clinical development of its potential Covid-19 vaccine and expand pipeline of other vaccine and treatment candidates.

Abogen's potential shot against the new coronavirus, which it is jointly developing with a research institute affiliated with Chinese military and Walvax Biotechnology, adopts the messenger RNA (mRNA) technology.

The candidate ARCoV is being tested in a Phase III clinical trial.

The fundraising was led by seven investors, including Singapore's state investment firm Temasek Holdings and Hillhouse-backed GL ventures, Abogen said in a statement.

REUTERS

A NEWSLETTER FOR YOU

Monday, 3.30 pm

Garage

The hottest news on all things startup and tech to kickstart your week.

Sign Up